ArticleScientific reports2025
Tumor extracellular matrix enhances invasive gene expression of breast cancer cells in 3D patient-derived scaffolds.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa.Infection · 2026Review
- Using biomaterial-based 3D in vitro cancer models to solve current clinical problems.British journal of cancer · 2026Review
- Emerging hallmarks and the rise of complexities and heterogeneity of tumor.Biochemistry and biophysics reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Extracellular matrix (ECM) remodeling in cancer provides an essential substructure for tumor progression. We utilized patient-derived scaffolds (PDS) to model tumor ECM changes and study their impact on cell behavior. PDS were obtained from breast tumor and normal healthy breast tissue by decellularizing surgically resected specimens. We used PDS to design a 3D culture of the breast cancer cell line MCF-7. We utilized bioinformatics pipeline to identify hub genes indicative of cell invasiveness, and assessed their expression using quantitative real-time PCR. Our decellularization protocol led to decellularization of tissues while preserving key ECM components. ECM components such as collagen, glycosaminoglycans, collagen IV, and vimentin were significantly overexpressed in tumor compared to normal PDS. In 3D cultures, cells cultured on normal PDS had significantly lower viability and proliferation. Moreover, cells cultured for 15 days on tumor PDS showed significant overexpression of hub genes, CAV1, CXCR4, CNN3, MYB, and TGFB1, and secreted higher levels of IL-6 (122.91 vs. 30.23 pg/10⁶ cells, P < 0.05), all markers of an aggressive breast cancer phenotype. Breast cancer cells fail to acquire aggressive features when cultured in an ECM lacking tumor-specific alterations. This underscores the potential of therapeutic approaches targeting the mechanobiological properties of the tumor ECM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.